MedTrace Logo

Prevalence of Hyperprolactinemia in Systemic Scleroderma

NCT04746313 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2025-12-23

No results posted yet for this study

Summary

Systemic sclerosis is an autoimmune and inflammatory disease characterized primarily by fibrosis and vascular involvement. We know that the immune system is disrupted in systemic sclerosis, but there are probably other mechanisms to explain the disease, including deregulation of certain proteins such as prolactin

Conditions

  • Sclerosis, Systemic
  • Scleroderma
  • Hyperprolactinemia

Interventions

BIOLOGICAL

blood test

* to analysis prolactin in healthy subjects and scleroderma patients * then to analysis in only scleroderma patients: thyroid-stimulating hormone (TSH), thyroxine (T4), luteinizing hormone (LH), oestradiol, follicle-stimulating hormone (FSH), BAFF (B-cell activating factor), IL-6 (interleukin 6) and endoglin

Sponsors & Collaborators

  • Association pour la Formation et la Recherche en Médecine Interne (AFORMI)

    collaborator UNKNOWN

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • David Launay, MD,PhD · University Hospital, Lille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-05-12
Completion
2021-05-12

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746313 on ClinicalTrials.gov